Tofacitinib

Based on the title and source metadata, this appears to be a regulatory update related to Tofacitinib, JAK inhibitor, and Medications. The original article is from DailyMed.

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.